Key result
Systemic chemotherapy achieves significant tumor regression or resolution in most of 6 primary cardiac lymphoma cases.
Why the study?
Primary cardiac lymphomas are rare and diagnostically challenging due to nonspecific clinical and imaging findings, where delayed diagnosis can cause rapid clinical deterioration.
In a rare case series of primary cardiac lymphomas, multimodality imaging and surgical biopsy were effective for diagnosis, and systemic chemotherapy led to significant tumor regression.
Answers are grounded in this paper and cite their sources.
Supports surgical biopsy and chemotherapy for primary cardiac lymphoma; extends scarce evidence in this rare disease but remains hypothesis-generating.
Primary cardiac lymphomas (PCLs) are rare and often present a diagnostic challenge because of nonspecific clinical and imaging findings. Delayed diagnosis may lead to rapid clinical deterioration. We report a case series of 6 patients with PCL diagnosed between 2021 and 2025 at 2 tertiary cardio-oncology centers, illustrating the diagnostic pathway, therapeutic strategies, and clinical outcomes. Multimodality imaging was essential for initial evaluation, but histopathologic confirmation was required in all cases. Surgical biopsy proved to be a safe and effective method for tissue diagnosis. Systemic chemotherapy resulted in significant tumor regression or complete resolution in most patients, whereas surgical debulking was reserved for those with hemodynamic compromise. This case series highlights key diagnostic and management considerations that may assist clinicians facing suspected PCL.
No takes yet. Share an insight, caveat, or question.
Pons-Riverola et al. (2026) studied this question. Systemic chemotherapy resulted in significant tumor regression or complete resolution in most of 6 patients with primary cardiac lymphoma, following safe diagnosis via surgical biopsy.
Synapse has enriched 10 related papers. Consider them for comparative context: